The US Food and Drug Administration has released long-awaited updated guidance on Diversity Action Plans. This guidance is stronger and very specific in places. How are sponsors, both large and small, responding? What effect will a diversity action plan have on site burden and on patients? How are clinical operations and regulatory affairs teams applying this US-focused guidance in global clinical trials?
Our trio of esteemed guests Aman Khera, Joan A Chambers, and Lya Rebelo will share their insights on what these questions and more mean for clinical research.
Life Sciences - In Focus: FDA Diversity Action Plans: Deciphering the Guidance and its Consequences
September 4, 4 pm (GMT+1) | 5 pm (CET) | 8 am (PDT) - Register now!
Panelists
Aman Khera
Joan A. Chambers
Senior Consultant
Tufts Center for the Study of Drug Development (Tufts CSDD)
Lya Rebelo
Commercial Enablement Manager
Citeline
Host
Karen M. Tkaczyk
Director of Sales – Life Sciences, Vistatec
Karen (MChem, Chemistry with French, University of Manchester; PhD, Chemistry, University of Cambridge) began her career as a development chemist, then for many years was a freelance translator, editor, and trainer on scientific writing and editing. At Vistatec, she leads sales for the Life Sciences division.